New Dimensions in Drug Development by Targeting Motor Enzymes
24 March 2022
- University Campus Bohunice (pavilion B11/ seminar room 132)
Dr. Andras Malnasi-Csizmadia
Eotvos Lorand University, Dept of Biochemistry
he main areas of interest are enzyme research, optopharmacology, and model-based drug design. Focused on the following specific areas: Molecular Tattoo, Mechanism of motor enzymes and force-related enzymatic processes and also in silico characterisation of enzymatic processes and interactions.
See more information at Dr. Malnasi-Csizmadia´s research group website.
About the lecture
Motor enzymes are the direct effector proteins responsible for movement and force production of the cells and organs i.e., contraction of different muscle types, cellular movements, cytokinesis and several other processes. Recently, these motor enzymes as potential drug targets have become the focus of drug discovery.
Related to muscle contraction one of the major medical issues is chronic muscle spasticity that disables self-supporting life management of 60 million patients with various nervous system injuries including stroke, multiplex sclerosis, traumatic brain and spinal cord injuries and cerebral palsy. The socio-economical cost of chronic muscle spasticity is comparable with that of cerebrovascular diseases. There is a high unmet medical need for an efficient antispastic drug because current muscle relaxants have as little as 37% efficacy and cause severe neurological and cardiovascular side effects due to targeting the central or peripheral nervous system.
We developed the first new-generation anti-spastic oral drug candidate, MPH-220, that specifically targets skeletal muscle myosin, the direct effector enzyme of muscle contraction. Due to its mechanism of action, MPH-220 has 100 % efficacy and no neurological or cardiovascular side effects. One of the major scientific challenges of the development was to create a highly specific compound because myosins responsible for the skeletal, smooth and cardiac muscle contraction are sequentially a structurally highly similar. In my talk I will present the story of the development of this drug candidate from the design of the compound to the clinical development. Also, I will briefly talk about economic and business strategies and the structures of my laboratory and Motorpharma our spin-off company that developed MPH-220.
Registration for lunch with the speaker /for Ph.D. students/
The sponsored lunch usually takes place in the Campus River restaurant. Please meet the speaker and other students at 12:45 at the reception desk at the main entrance (building B22, see the map below).